KAUST ·
KAUST researchers suggest antibody testing can complement PCR tests to reduce false negatives in COVID-19 diagnosis. PCR tests can produce false negative results. Immunodiagnostic tests could help identify unknowingly spreading the disease. Why it matters: Improving diagnostic accuracy is critical for effective pandemic control and public health management in Saudi Arabia and globally.
KAUST ·
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
MBZUAI ·
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
KAUST ·
KAUST President announced a mandatory COVID-19 screening program for employees and students from November 1-5. The program aims to provide snapshots of COVID-19 prevalence in the community to inform healthcare demands and future plans. The university targets 5,000 individual swabs in partnership with the Ministry of Health, and participation is crucial for the program's success. Why it matters: This proactive measure enables KAUST to maintain a safe environment and continue reopening the campus, setting an example for managing the pandemic sustainably in the region.
KAUST ·
KAUST professor David Ketcheson uses mathematical modeling to understand COVID-19 transmission. He applies differential equations to explain the progression of SARS-CoV-2, utilizing the SIR model to predict the spread. Ketcheson's analysis suggests that the reproduction number for COVID-19 could be as high as 5, emphasizing the need for social distancing. Why it matters: This highlights the role of mathematical modeling and data analysis in understanding and predicting the spread of infectious diseases, particularly in the context of pandemic response.
KAUST ·
KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.
KAUST ·
KAUST is developing a phased reopening plan in response to the COVID-19 pandemic. The plan addresses the gradual return of operations, including laboratories, innovation ecosystem, students, faculty, and staff. It aims to balance community protection with minimizing disruption, focusing on a phased approach to a "new normal." Why it matters: This signals a move towards resuming research activities and on-site work at a leading Saudi research institution, impacting the pace of AI and technology development in the Kingdom.
KAUST ·
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.